本文章的学术内容和语言评估
本文章的CrossCheck查重和Google搜索
本文章的学术规范
本文章的引用
本文章的通讯作者
本文章的研究领域
本文章的类型
本文章的开放获取政策
本文章的Google引用次数
本文章的点击和下载次数
- 本文章浏览次数 (6678)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 7, 2024 (publication date) through Mar 13, 2025
本文章的被引频次
本文章的期刊信息
出版物名称
World Journal of Gastroenterology
ISSN
1007-9327
本文章的出版商
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kanu JE, Soldera J. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol 2024; 30(9): 1213-1223 [PMID: 38577188 DOI: 10.3748/wjg.v30.i9.1213] |
|---|---|
| URL: | https://www.wjgnet.com/1009-3079/full/v30/i9/1213.htm |
| 编号 | Citing Articles |
| 1 |
Younghee Choe. Efficacy of Vonoprazan-Tetracycline Dual Therapy in the Initial Treatment of Penicillin-Allergic Helicobacter pylori Infections. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2024; 24(4): 391 doi: 10.7704/kjhugr.2024.0062
|
| 2 |
Xingsheng Zuo, Qingli Shen, Jing Luo, Yaqin Wang, Chenglong Zhao. Clarithromycin sustained-release tablet may be an improper therapy for the eradication of Helicobacter pylori. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241275332
|
| 3 |
Xiaolei Wang, Guigen Teng, Xinhong Dong, Yun Dai, Weihong Wang. The efficacy and safety of a simple 14-day vonoprazan-minocycline dual therapy for Helicobacter pylori eradication: a retrospective pilot study. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241299734
|
| 4 |
Ayman Elbehiry, Adil Abalkhail, Nuha Anajirih, Fahad Alkhamisi, Mohammed Aldamegh, Abdullah Alramzi, Riyad AlShaqi, Naif Alotaibi, Abdullah Aljuaid, Hilal Alzahrani, Feras Alzaben, Mohammed Rawway, Mai Ibrahem, Moustafa H. Abdelsalam, Nermin I. Rizk, Mohamed E. A. Mostafa, Moneef Rohail Alfaqir, Husam M. Edrees, Mubarak Alqahtani. Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control. Diseases 2024; 12(12): 311 doi: 10.3390/diseases12120311
|
| 5 |
Zefeng Zhang, Sitong Chen, Shudan Li, Yadan Zheng, Lifei Mai, Xiaoguang Zhang. Association of Helicobacter pylori related chronic atrophic gastritis and gastric cancer risk: a literature review. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1504749
|
| 6 |
Sergey M Kotelevets. Risks of anti-<i>Helicobacter</i> therapy and long-term therapy with antisecretory drugs. World Journal of Gastroenterology 2025; 31(4): 101933 doi: 10.3748/wjg.v31.i4.101933
|
| 7 |
Zi-Teng Wang, Wen-Tao Tan, Jia-Li Huang, Peng-Fei Zhang, Qian Li, Miao-Miao Wang, Ming-Ming Meng, Hui Su, Chun-Mei Guo, Hong Liu. Correlation Between Gastroesophageal Reflux Disease and Small Intestinal Bacterial Overgrowth: Analysis of Intestinal Microbiome and Metabolic Characteristics. Journal of Inflammation Research 2025; : 33 doi: 10.2147/JIR.S487185
|
| 8 |
Abdulrhman Khaled Al Abdulqader, Turki Abdullah Alamri, Mahdi Abdullah Alhamad, Somaia Shehab El‐Deen, Abdallah Essa, Raed Abdullah Alfayez, Baqer Mohammed Albaqshi, Adnan Salah Almajed, Mohammed Yousef Alhassan, Ali Essa, Ahmed Abdullah Albadrani, Omar Alomair, Bashaeer Abdullh Al Jalal, Mohammed Yousef Almulhim, Abdullah Alotaibi, Ehab Darwish. First‐Line Levofloxacin‐Based Triple Therapy Versus Standard Bismuth‐Based Quadruple Therapy for Helicobacter pylori Eradication in Saudi Arabia: A Retrospective Single‐Center Study. Health Science Reports 2025; 8(2) doi: 10.1002/hsr2.70432
|
| 9 |
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Minghui Sun. Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis. Helicobacter 2024; 29(6) doi: 10.1111/hel.13150
|
| 10 |
Wenwen Gao, Qian Wang, Xiang Zhang, Lu Wang. Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials. International Journal of Immunopathology and Pharmacology 2024; 38 doi: 10.1177/03946320241286866
|
| 11 |
Giuseppina Malcangi, Angelo Michele Inchingolo, Lucia Casamassima, Irma Trilli, Laura Ferrante, Francesco Inchingolo, Andrea Palermo, Alessio Danilo Inchingolo, Gianna Dipalma. Effectiveness of Herbal Medicines with Anti-Inflammatory, Antimicrobial, and Antioxidant Properties in Improving Oral Health and Treating Gingivitis and Periodontitis: A Systematic Review. Nutrients 2025; 17(5): 762 doi: 10.3390/nu17050762
|
| 12 |
Sinéad M. Smith, Breida Boyle, Martin Buckley, Conor Costigan, Maeve Doyle, Richard Farrell, M. Syafiq Ismail, David Kevans, Sean Nugent, Anthony O’Connor, Colm O’Morain, Vikrant Parihar, Cristín Ryan, Deirdre McNamara. The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland. European Journal of Gastroenterology & Hepatology 2024; 36(8): 1000 doi: 10.1097/MEG.0000000000002796
|
| 13 |
Zejun Gao, Jinlin Ge, Ruoshi Xu, Xiaoyan Chen, Zhenzhai Cai. Potential application of ChatGPT in Helicobacter pylori disease relevant queries. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1489117
|
| 14 |
Abdollah Safikhani Mahmoodzadeh, Elham Moazamian, Seyedeh Azra Shamsdin, Gholam Abas Kaydani. Altered Cytokine Production in Patients with Helicobacter pylori Infection. Middle East Journal of Digestive Diseases 2024; 16(4): 235 doi: 10.34172/mejdd.2024.398
|
| 15 |
Anhye Kim, Dongseong Shin, Youlim Seo, Deborah Kang, Yang Won Min, In Hee Kim, Jungryul Kim. Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker. Advances in Therapy 2025; 42(3): 1570 doi: 10.1007/s12325-025-03127-5
|